BACKGROUND AND OBJECTIVES: Three year post-surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND) and those with negative sentinel node dissection and negative axillary lymph node dissection (ALND) in the NSABP B-32 trial. METHODS:A total of 1,975 ALND and 2,008 SLND node negative breast cancer patients had shoulder range of motion and arm volumes assessed along with self reports of arm tingling and numbness. Relative shoulder abduction deficits and relative arm volume differences between ipsilateral and contralateral arms were calculated. RESULTS:Shoulder abduction deficits >or=10% peaked at 1 week for the ALND (75%) and SLND (41%) groups. Arm volume differences >or=10% at 36 months were evident for the ALND (14%) and SLND (8%) groups. Numbness and tingling peaked at 6 months for the ALND (49%, 23%) and SLND (15%, 10%) groups. Logistic regression correlates of residual morbidity included treatment group, age, handedness, tumor size, systemic chemotherapy, and radiation to the axilla. CONCLUSIONS: Although residual morbidity for both treatment groups was evident, the results of the NSABP B-32 study indicate the superiority of the SLND compared to the ALND treatment approach relative to post-surgical morbidity outcomes over a 3-year follow-up period. (c) 2010 Wiley-Liss, Inc.
RCT Entities:
BACKGROUND AND OBJECTIVES: Three year post-surgical morbidity levels were compared between patients with negative sentinel lymph node dissection alone (SLND) and those with negative sentinel node dissection and negative axillary lymph node dissection (ALND) in the NSABP B-32 trial. METHODS: A total of 1,975 ALND and 2,008 SLND node negative breast cancerpatients had shoulder range of motion and arm volumes assessed along with self reports of arm tingling and numbness. Relative shoulder abduction deficits and relative arm volume differences between ipsilateral and contralateral arms were calculated. RESULTS: Shoulder abduction deficits >or=10% peaked at 1 week for the ALND (75%) and SLND (41%) groups. Arm volume differences >or=10% at 36 months were evident for the ALND (14%) and SLND (8%) groups. Numbness and tingling peaked at 6 months for the ALND (49%, 23%) and SLND (15%, 10%) groups. Logistic regression correlates of residual morbidity included treatment group, age, handedness, tumor size, systemic chemotherapy, and radiation to the axilla. CONCLUSIONS: Although residual morbidity for both treatment groups was evident, the results of the NSABP B-32 study indicate the superiority of the SLND compared to the ALND treatment approach relative to post-surgical morbidity outcomes over a 3-year follow-up period. (c) 2010 Wiley-Liss, Inc.
Authors: David N Krag; Thomas B Julian; Seth P Harlow; Donald L Weaver; Taka Ashikaga; John Bryant; Richard M Single; Norman Wolmark Journal: Ann Surg Oncol Date: 2004-03 Impact factor: 5.344
Authors: Rebecca J Tsai; Leslie K Dennis; Charles F Lynch; Linda G Snetselaar; Gideon K D Zamba; Carol Scott-Conner Journal: Ann Surg Oncol Date: 2009-04-14 Impact factor: 5.344
Authors: Anand David Purushotham; Sara Upponi; Manfred Borislav Klevesath; Lynda Bobrow; Keith Millar; Jonathan Peter Myles; Stephen William Duffy Journal: J Clin Oncol Date: 2005-07-01 Impact factor: 44.544
Authors: Anne Fleissig; Lesley J Fallowfield; Carolyn I Langridge; Leigh Johnson; Robert G Newcombe; J Michael Dixon; Mark Kissin; Robert E Mansel Journal: Breast Cancer Res Treat Date: 2005-09-15 Impact factor: 4.872
Authors: Robert E Mansel; Lesley Fallowfield; Mark Kissin; Amit Goyal; Robert G Newcombe; J Michael Dixon; Constantinos Yiangou; Kieran Horgan; Nigel Bundred; Ian Monypenny; David England; Mark Sibbering; Tholkifl I Abdullah; Lester Barr; Utheshtra Chetty; Dudley H Sinnett; Anne Fleissig; Dayalan Clarke; Peter J Ell Journal: J Natl Cancer Inst Date: 2006-05-03 Impact factor: 13.506
Authors: David N Krag; Stewart J Anderson; Thomas B Julian; Ann M Brown; Seth P Harlow; Takamaru Ashikaga; Donald L Weaver; Barbara J Miller; Lynne M Jalovec; Thomas G Frazier; R Dirk Noyes; André Robidoux; Hugh M C Scarth; Denise M Mammolito; David R McCready; Eleftherios P Mamounas; Joseph P Costantino; Norman Wolmark Journal: Lancet Oncol Date: 2007-10 Impact factor: 41.316
Authors: P Del Bianco; G Zavagno; P Burelli; G Scalco; L Barutta; P Carraro; P Pietrarota; G Meneghini; T Morbin; G Tacchetti; P Pecoraro; V Belardinelli; G L De Salvo Journal: Eur J Surg Oncol Date: 2007-07-05 Impact factor: 4.424
Authors: Umberto Veronesi; Giovanni Paganelli; Giuseppe Viale; Alberto Luini; Stefano Zurrida; Viviana Galimberti; Mattia Intra; Paolo Veronesi; Chris Robertson; Patrick Maisonneuve; Giuseppe Renne; Concetta De Cicco; Francesca De Lucia; Roberto Gennari Journal: N Engl J Med Date: 2003-08-07 Impact factor: 91.245
Authors: Dionysios Dellaportas; Andreas Koureas; John Contis; Panagis M Lykoudis; Irene Vraka; Dimitrios Psychogios; Agatha Kondi-Pafiti; Dionysios K Voros Journal: Breast Care (Basel) Date: 2015-07-10 Impact factor: 2.860
Authors: Wolfram Malter; Christian Eichler; Bettina Hanstein; Peter Mallmann; Johannes Holtschmidt Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: Stephanie R Land; Jacek A Kopec; Thomas B Julian; Ann M Brown; Stewart J Anderson; David N Krag; Nicholas J Christian; Joseph P Costantino; Norman Wolmark; Patricia A Ganz Journal: J Clin Oncol Date: 2010-08-02 Impact factor: 44.544
Authors: Jean O'Toole; Lauren S Jammallo; Cynthia L Miller; Melissa N Skolny; Michelle C Specht; Alphonse G Taghian Journal: Oncologist Date: 2013-04-10
Authors: Vered Stearns; Amanda Blackford; Jill Kessler; Eman Sbaity; Mehran Habibi; Nagi Khouri; Cindy S Lee; Evelyn May; Stacie Jeter; Camila Sahebi; Christina Shehata; Karineh Tarpinian; Lisa Jacobs; David Eisner Journal: Breast Cancer Res Treat Date: 2015-03-20 Impact factor: 4.872
Authors: I Barco; C Chabrera; A García-Fernández; M Fraile; S González; L Canales; J M Lain; C González; M C Vidal; E Vallejo; J Deu; A Pessarrodona; N Giménez; M García Font Journal: Clin Transl Oncol Date: 2016-11-28 Impact factor: 3.405